BioIVT has acquired XenoTech, a provider of products and services for preclinical testing that specialises in ADME, DMPK and DDI testing of potential drug candidates.
Through the acquisition, BioIVT aims to expand the portfolio of research models and services that are available to its clients to support their R&D function.
“XenoTech has a well-established and excellent reputation for producing microsomes, subcellular fractions, and for designing and implementing ADME-Tox studies on a contract research basis,” said BioIVT Chief Executive Officer Dr Richard Haigh.
XenoTech’s product lines complement BioIVT’s portfolio of hepatocytes and other hepatic products. The company’s expertise also links with BioIVT’s drug transporter research, B-CLEAR® disposition studies, long-term HEPATOPAC® models, and other proprietary methodologies.
It is hoped that these combined product portfolios “will enable smarter science and accelerate medical breakthroughs…by delivering personalised biospecimen solutions to life science and diagnostic industries” Haigh added.
XenoTech will continue to operate out of its headquarters in Kansas City, KS, USA.
